Trial reportCritical care (London, England)2026
Suppression of microbial burden to reduce pneumonia in critical illness: the SMURF feasibility pilot study.
Trial report in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06867458 (Steriwave ICU Pilot Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Steriwave ICU Pilot Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNasal antimicrobial photodynamic therapy (aPDT) is a non-antibiotic decolonization strategy with potential to reduce ICU-acquired infections without contributing to antimicrobial resistance. We conducted a feasibility pilot to evaluate implementation of intranasal aPDT in critically ill adults and to generate preliminary estimates of microbiologic and clinical outcomes to inform a future definitive trial.
designProspective, single-center, non-randomized feasibility pilot study with sequential control and intervention phases.
settingAdult mixed medical–surgical intensive care units at a tertiary academic hospital. PATIENTS: Adults ≥ 19 years with an expected ICU stay > 48 h.
interventionDuring the intervention phase, patients received intranasal aPDT every 48 h until ICU discharge. Control-phase patients received standard ICU care without nasal decolonization. Nasal swabs were obtained at ICU admission and every four days. MAIN FEASIBILITY OUTCOMES: Recruitment rate, protocol adherence, safety, data completeness, and ability to adjudicate pneumonia events using blinded, rule-based criteria aligned with CDC/NHSN definitions.
resultsA total of 227 patients were analyzed (126 control, 101 intervention). Recruitment targets were met. Adherence to scheduled nasal swab collection was 97.7%. During the intervention phase, 57.8% of scheduled aPDT treatments were delivered in full and 12.0% partially delivered. No intervention-related serious adverse events were observed. Pneumonia adjudication was completed with high inter-system concordance and minimal missing data, supporting adequacy of data capture tools. Exploratory analyses demonstrated significantly lower early cumulative nasal pathogen burden in the intervention group (p < 0.01). The incidence of adjudicated VAP/HAP was 9.0 per 1,000 ICU patient-days during the intervention phase compared with 14.9 per 1,000 ICU patient-days during the control phase (incidence rate ratio 0.61, 95% CI 0.31–1.17, a difference that was not statistically significant). A hierarchical composite endpoint incorporating pneumonia, microbiologic clearance, and cumulative pathogen burden yielded a win ratio of 1.29 (95% CI 0.74–2.31) favoring treatment.
conclusionsImplementation of nasal aPDT in the ICU was feasible and safe, with high sampling adherence and successful blinded adjudication. Exploratory signals of reduced pathogen burden and lower though not statistically significant, pneumonia incidence provide preliminary support for progression to a multicenter randomized trial powered for clinical endpoints.
trial registrationNCT06867458 clinicaltrials.gov, Registration date March 6, 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.